Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.
作者信息
Goldberg Tamara, Berrios-Colon Evangelina
出版信息
P T. 2013 Jan;38(1):23-6.
Abstract
摘要
相似文献
1
2
Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.临床试验与现实世界中的治疗价值：以醋酸阿比特龙（泽珂）治疗瑞典接受化疗后的转移性去势抵抗性前列腺癌患者为例。
Scand J Urol. 2016 Aug;50(4):286-91. doi: 10.3109/21681805.2016.1172254. Epub 2016 Apr 25.
3
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.在健康男性受试者中，新型醋酸阿比特龙颗粒制剂 SUVN-1105 与 Zytiga 的生物等效性、食物影响和比较药代动力学。
Cancer Chemother Pharmacol. 2024 Mar;93(3):253-264. doi: 10.1007/s00280-023-04629-1. Epub 2023 Dec 29.
4
Remarkable response to abiraterone acetate in castration-resistant prostate cancer patient with aggressive liver metastasis.醋酸阿比特龙对伴有侵袭性肝转移的去势抵抗性前列腺癌患者有显著疗效。
IJU Case Rep. 2018 Nov 12;2(1):12-14. doi: 10.1002/iju5.12026. eCollection 2019 Jan.
5
Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.阿比特龙或恩杂鲁胺治疗去势抵抗性前列腺癌患者的抗雄激素撤退综合征的影响。
Int J Urol. 2020 Dec;27(12):1109-1115. doi: 10.1111/iju.14366. Epub 2020 Sep 15.
6
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.一项关于日本转移性去势抵抗性前列腺癌患者中醋酸阿比特龙序贯多西他赛治疗的多中心回顾性分析。
Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.
7
Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.化疗前醋酸阿比特龙。去势抵抗性前列腺癌治疗方案建议。
Actas Urol Esp. 2014 Jun;38(5):327-33. doi: 10.1016/j.acuro.2013.10.008. Epub 2013 Dec 15.
8
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.醋酸阿比特龙：在转移性去势抵抗性前列腺癌中的应用指南。
Drugs Aging. 2012 Mar 1;29(3):243-248. doi: 10.2165/11209160-000000000-00000.
9
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial.恩杂鲁胺与阿比特龙作为去势抵抗性前列腺癌一线内分泌治疗的比较：一项多中心随机3期试验方案
JMIR Res Protoc. 2018 Jul 27;7(7):e11191. doi: 10.2196/11191.
10
Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.醋酸阿比特龙联合泼尼松治疗去势抵抗性前列腺癌患者的安全性和有效性：一项前瞻性、观察性、上市后监测研究。
Jpn J Clin Oncol. 2021 Aug 30;51(9):1452-1461. doi: 10.1093/jjco/hyab077.
引用本文的文献
1
Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer.提出自噬抑制作为一种治疗策略与前列腺癌雄激素靶向治疗联合应用的理由。
Cancers (Basel). 2023 Oct 18;15(20):5029. doi: 10.3390/cancers15205029.
2
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.2011 年初至 2021 年底，获 FDA 批准的用于实体瘤的小分子化合物药物。
Molecules. 2022 Mar 31;27(7):2259. doi: 10.3390/molecules27072259.
3
Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation.桑黄酮，一种通过抑制CYP17A1治疗前列腺癌的新候选药物：分子对接和动力学模拟研究
Plants (Basel). 2021 Sep 14;10(9):1912. doi: 10.3390/plants10091912.
4
Hyperpolarisation of weakly binding N-heterocycles using signal amplification by reversible exchange.利用可逆交换信号放大实现弱结合氮杂环的超极化
Chem Sci. 2021 Mar 23;12(16):5910-5917. doi: 10.1039/d0sc06907h.
5
Abiraterone suppresses irradiated lung cancer cells-induced angiogenic capacities of endothelial cells.阿比特龙抑制辐照肺癌细胞诱导的内皮细胞血管生成能力。
J Bioenerg Biomembr. 2021 Jun;53(3):343-349. doi: 10.1007/s10863-021-09894-4. Epub 2021 Apr 5.
6
CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines.CYP17A1与雄激素受体在前列腺癌组织及癌细胞系中的表达
Curr Urol. 2019 Nov;13(3):157-165. doi: 10.1159/000499276. Epub 2019 Nov 13.
7
Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats.醋酸阿比特龙与 NVP-BEZ235 联合作用对大鼠前列腺肿瘤进展的影响。
Horm Cancer. 2018 Jun;9(3):175-187. doi: 10.1007/s12672-018-0323-z. Epub 2018 Jan 23.
8
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.对符合阿比特龙或恩杂鲁胺治疗条件的转移性去势抵抗性前列腺癌患者进行AR-V7检测的成本节约分析。
Prostate. 2016 Dec;76(16):1484-1490. doi: 10.1002/pros.23232. Epub 2016 Jul 12.
9
Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.使用小鼠胚胎干细胞双荧光报告基因检测法对神经毒性化合物进行指纹识别。
Arch Toxicol. 2017 Jan;91(1):365-391. doi: 10.1007/s00204-016-1690-2. Epub 2016 Mar 25.
10
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.阿比特龙在未经化疗及接受多西他赛治疗的转移性去势抵抗性前列腺癌患者中的群体药代动力学分析。
Clin Pharmacokinet. 2014 Dec;53(12):1149-60. doi: 10.1007/s40262-014-0178-6.
本文引用的文献
1
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men.醋酸阿比特龙在健康男性中的开放标签、I 期药代动力学研究。
Cancer Chemother Pharmacol. 2012 Jun;69(6):1583-90. doi: 10.1007/s00280-012-1865-3. Epub 2012 Apr 18.
2
Cancer statistics, 2012.癌症统计数据，2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
3
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.在去势抵抗性前列腺癌中，使用阿比特龙抑制 CYP17A1 产生耐药性：诱导甾体生成和雄激素受体剪接变体。
Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.
4
Expanding treatment options for metastatic prostate cancer.扩大转移性前列腺癌的治疗选择。
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
5
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
6
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.醋酸阿比特龙的 CYP17 抑制剂的 I 期临床试验表明，在接受过酮康唑治疗的去势抵抗性前列腺癌患者中具有临床活性。
J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.
7
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.醋酸阿比特龙抑制 CYP17 可显著持久抑制多西他赛治疗失败后的去势抵抗性前列腺癌。
J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16.
8
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.醋酸阿比特龙联合泼尼松治疗多西他赛治疗失败的去势抵抗性前列腺癌的多中心 II 期研究。
J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16.
9
The 2010 NCCN clinical practice guidelines in oncology on prostate cancer.2010年美国国立综合癌症网络（NCCN）肿瘤学临床实践指南：前列腺癌
J Natl Compr Canc Netw. 2010 Feb;8(2):145. doi: 10.6004/jnccn.2010.0010.
10
Targeting the androgen receptor pathway in prostate cancer.针对前列腺癌中的雄激素受体通路
Curr Opin Pharmacol. 2008 Aug;8(4):440-8. doi: 10.1016/j.coph.2008.07.005. Epub 2008 Aug 12.
Zotero 插件